Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4903 - The prognostic significance of Distant Metastasis Free Interval (DMFI) in BRAF mutant advanced melanoma patients treated with first line targeted therapy


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Targeted Therapy;  Melanoma


Dimitrios Bafaloukos


Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377


D. Bafaloukos1, H. Linardou1, P. Diamantopoulos2, T. Sergentanis3, A. Laskarakis1, K. Giati1, A. Tarampikou1, A. Anastasopoulou2, H. Gogas2

Author affiliations

  • 1 A' Oncology Dept, Metropolitan Hospital, 18547 - Athens/GR
  • 2 1st Dept Of Medicine, Laikon Hospital, Medical School, National and Kapodestrian University of Athens, Athens/GR
  • 3 Dept Of Hygiene, Epidemiology And Medical Statistics, Medical School, National and Kapodestrian University of Athens, Athens/GR


Abstract 4903


Prognostic models are investigated for advanced melanoma patients treated with targeted therapy. This study aims to identify the relationship between DMFI and outcome of 1st line targeted therapy in BRAF mutant (BRAFmut) patients.


BRAFmut patients identified from 2 referral centres were assigned to 3 prognostic groups: A (PS 0, Metastatic sites ≤3, LDH normal, CNS not involved), B (PS 1, Metastatic sites ≤3, LDH >1-2ULN, CNS not involved), C (PS 2, Metastatic sites >3, LDH ≥2ULN, CNS involved or not). Factors analysed: Distant Metastasis Free Interval (DMFI from primary melanoma to 1st distant metastasis), Post Relapse Progression Free Survival (PRPFS post relapse to BRAFi), Post Relapse Survival (PRS), number of metastatic sites, LDH, CNS involvement, PS. Univariate and multivariate Cox regression analysis was used adjusted with the 3 prognostic groups. Statistical analysis with STATA/SE V13.0.


From 380 advanced melanoma patients, 161 BRAFmut patients received 1st line BRAFi only (101) or BRAFi+MEKi (60). Patients relapsed from primary at a median DMFI 12 months (range 0-185) and were included in the 3 prognostic groups (Group A 27, Group B 72, Group C 56). To study DMFI significance, we defined 2 patient groups according to DMFI: DMFI


Patients with BRAFmut advanced melanoma and DMFI

Clinical trial identification

Legal entity responsible for the study

A' Oncology Dept, Metropolitan Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.